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Abstract
Objective—Determine efficacy of three non-hormonal therapies for improving menopause-
related quality of life (QOL) in women with vasomotor symptoms (VMS).
Methods—12-week 3×2 randomized, controlled, factorial design trial. Peri- and postmenopausal
women, ages 40-62 years, were randomized to yoga (n=107), exercise (n=106), or usual activity
(n=142), and also randomized to double-blind comparison of omega-3 (n=177) or placebo (n=178)
capsules. Interventions: 1) weekly 90-minute yoga classes with daily at-home practice; 2)
individualized facility-based aerobic exercise training 3 times/week; and 3) 0.615 gram omega-3
supplement, 3 times/day. Outcomes: Menopausal Quality of Life Questionnaire (MENQOL) total
and domain (VMS, psychosocial, physical and sexual) scores.
Results—Among 355 randomized women, average age 54.7 years, 338 (95%) completed 12-
week assessments. Mean baseline VMS frequency was 7.6/day and mean baseline total MENQOL
score was 3.8 (range 1-8 from better to worse) with no between-group differences. For yoga
compared to usual activity, baseline to 12-week improvements were seen for MENQOL total -0.3
(95% CI -0.6 to 0.0, p=0.02), and VMS (p=0.02) and sexuality (p=0.03) domain scores. For
exercise and omega-3 compared to controls, improvements in baseline to 12-week total MENQOL
scores were not observed. Exercise showed benefit in the MENQOL physical domain score at 12-
weeks (p=0.02).
Conclusion—All women become menopausal and many seek medical advice on ways to
improve quality of life; little evidence-based information exists. We found, among healthy
sedentary menopausal women, yoga appears to improve menopausal QOL - the clinical
significance of our finding is uncertain due to modest effect.
Keywords
menopause quality of life; yoga; exercise; omega-3; randomized trial
INTRODUCTION
More than 38 million US women ages 45-64 years old (88%) experience daytime hot flashes
or night sweats during the menopausal transition.1 Hot flashes and night sweats or
vasomotor symptoms (VMS) are the cardinal symptoms of menopause. However, other
menopausal symptoms - often adversely affected by VMS frequency and bother,2 such as
sleep and mood disturbances, pain, difficulty concentrating and diminished energy - can
affect daily functioning in work, social, leisure and sexual activities.3 Medical resources
expended to alleviate these problems are substantial4 and there is a compelling need for
effective treatments to relieve menopausal symptoms in midlife women.
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Among symptomatic peri- and postmenopausal women with vasomotor symptoms (VMS),
hormone therapy (HT) has demonstrated an improvement in QOL.5 Due to risks associated
with HT among postmenopausal women6 alternative lower risk behavioral therapies have
been proposed for the treatment of VMS. Studies regarding benefit of behavioral
interventions for improving menopause-related QOL are less robust, but suggest that
yoga7-12 and exercise,13,14 may be beneficial. Findings across studies have been
inconsistent, perhaps because of different measures and outcomes of interest.14 Yoga
findings, in particular, are limited by a paucity of studies, small sample sizes and lack of
control groups.
Non-phytoestrogenic supplements are widely used by midlife women but have not been
specifically examined for improved midlife QOL.15 Omega-3 supplements containing
polyunsaturated fatty acids (PUFAs) are among the most widely consumed supplements for
a variety of medical conditions.16 Studies suggest omega-3s modulate serotonergic and
dopaminergic neurotransmission17-19 and may alleviate VMS.20 Two small randomized
trials have examined the efficacy of omega-3s in the treatment of VMS20,21 with conflicting
results.
We conducted a factorial design randomized controlled trial to evaluate the efficacy of yoga,
exercise and omega-3s on VMS frequency and bother. We found no benefit from any of
these interventions for VMS, but suggestive evidence that self-reported sleep quality and
depressive symptoms improved slightly with exercise and yoga (findings previously
reported, not adjusted for multiple comparisons).22-25 In this analysis, we report findings on
the impact of yoga, exercise and omega-3s on menopause-related quality of life.
MATERIALS AND METHODS
Study design
Details about the MsFLASH Research Network, study design, and protocols are
published.22-26 Briefly, we performed a multi-site, 3 by 2 factorial randomized controlled
trial. Eligible women were randomized to 12 weeks of yoga, exercise, or usual activity, and
simultaneously randomized to 1.8 g/day of omega-3 or placebo capsules. The study was
approved by the Institutional Review Boards of all clinical sites and the Data Coordinating
Center (DCC), and all participants provided written informed consent. The DCC performed
centralized training, and monitored maintenance of the standardized protocol, fidelity to the
intervention, and participant adherence.
Eligibility, Screening, Randomization, and Blinding
Participants were recruited February 2011 through January 2012, primarily by mass-mailing
to women ages 40-62 years, using purchased lists and health-plan enrollment files, at three
sites (Indianapolis, Oakland, and Seattle). Eligible women were in the menopausal transition
or postmenopausal. Screening was performed centrally with standardized inclusion,
exclusion, and final eligibility criteria across sites.22,24
Randomization was conducted in a secure central web-based database, utilizing a dynamic
randomization algorithm to maintain comparability between study groups with respect to
clinical site. An unequal allocation was employed for the behavioral interventions (3:3:4,
yoga:exercise:control) and equal allocation employed for omega-3 and placebo treatments,
provided in masked identical capsules and containers.
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Interventions (details described elsewhere)24
Yoga:26—The yoga intervention (studio and home practice) emphasized a practice of
“cooling” breathing exercises, 11-13 poses (Asanas: restorative, inverted, lateral bends or
twists, forward bends, and counter-poses) previously suggested for VMS relief,7,27 and
guided meditation (Yoga Nidra). Instruction was provided during 12, weekly, 90-minute
classes. Daily home practice was expected for 20 minutes on days not attending class.
Exercise:23—The exercise intervention consisted of 12 weeks of three, individual
cardiovascular conditioning training sessions/week at local fitness facilities, supervised by
trained, certified exercise trainers. The targeted training heart rate was 50-60% of the heart
rate reserve for the first month and 60-70% for the remainder of the intervention
(approximately 125-145 beats/minute). Women exercised 40-60 minutes/session to achieve
the energy expenditure goal of 16 kcal/kg (about 1,000-1,500 kcals/week).
Usual Activity—Women in the usual activity group were instructed to follow their usual
physical activity behavior and were asked not to begin yoga or a new exercise regimen.
Omega-3 and Placebo Capsules:25—To standardize the expectation of benefit, all
women in both behavioral interventions and the usual activity group received either a
placebo containing olive oil or an active omega-3 capsule. The omega-3 supplement
contained 425 mg ethyl eicosapentaenoic acid, 100 mg docosahexaenoic acid and 90 mg of
other omega-3s. All capsules (placebo and omega-3) contained natural lemon oil rosemary
extract and vitamin E.
Follow-up and compensation
Participants were contacted by study staff masked to pill randomization assignment to
encourage pill compliance and to evaluate tolerance at 2 and 6-weeks. Participants were
compensated $50 after each clinic visit for a possible total of $150.
Data collection
Outcomes (baseline to 12-week change): Menopause Quality of Life
(MENQOL), total and specific domains—The MENQOL (range 1-8) is a 29-item
assessment of menopause-related QOL.28 Scoring generates a total score and 4 domain
scores (vasomotor, physical, psychosocial, sexual functioning); higher scores on all scales
indicate poorer quality of life. Women were asked whether an item was experienced in the
past four weeks. Each item score includes non-endorsement “1” or endorsement “2” plus the
bother score (0-6), for a maximum score of 8. The domain-specific score is the mean of the
item scores within that domain. The total MENQOL score is the mean of the specific
domain scores. Validity, internal consistency, reliability and responsiveness to change are
adequate to excellent.28,29
Other Measures (Covariates)—Demographic factors were assessed by baseline
questionnaire. Weight and height were measured at baseline and body mass index (BMI, kg/
m2) calculated. Frequency and severity of VMS were recorded retrospectively on daily
diaries completed in the morning for night sweats and in the evening for daytime hot flashes.
Standardized and validated baseline questionnaires (covariates and possible effect modifiers)
included: insomnia severity (7-item Insomnia Severity Index (ISI));30 subjective sleep
quality (Pittsburgh Sleep Quality Index (PSQI)),31,32 depressive symptoms (8-item scale
from the Patient Health Questionnaire (PHQ-8))33 and anxiety (7-item Generalized Anxiety
Disorder scale (GAD-7)).34
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Additional individual validated menopause QOL measures included the Hot Flash-Related
Daily Interference Scale (HFRDIS),35 Perceived Stress Scale (PSS),32 Pain Intensity,
Interference with Enjoyment of Life, and Interference with General Activity scale (PEG)33
and Female Sexual Function Index (FSFI),36 collected at baseline and 12-weeks.
Statistical analyses
The intent-to-treat analysis included all randomized participants with response data, which
were collected regardless of intervention adherence. Baseline characteristics were compared
between treatment groups using t-tests or chi-square tests.
Primary analyses consisted of treatment group contrasts from linear regression models
summarizing each outcome (total MENQOL and 4 domains) at 12-weeks as a function of
treatment assignment, adjusting each model for clinical center, concurrent intervention
assignment, and baseline value of the outcome measure. Treatment group comparisons
included yoga vs. usual activity, exercise vs. usual activity, and omega-3 vs. placebo.
Analyses comparing the treatment effects of yoga and exercise were adjusted for omega-3
assignment, and the omega-3 analyses were adjusted for the behavioral intervention
assignment. Sensitivity analyses were conducted to determine if the intervention effects
differed among women who were adherent22-24 to the intervention.
Additional analyses assessed treatment group contrasts from linear regression models
summarizing the HFRDIS (hot flash interference), PSS (stress), PEG (pain) and FSFI
(sexual function) scores - at 12-weeks as a function of treatment assignment, adjusting each
model for clinical center, concurrent intervention assignment, and baseline value of the
outcome measure.
We hypothesized that the intervention effects on the total MENQOL might be modified by
symptom thresholds measured at baseline: anxiety (GAD-7 continuous), depressive
symptoms (PHQ-8 continuous), poor sleep quality (PSQI > 8) or moderate to severe
insomnia (ISI > 14). Tests of interaction between treatment assignment and each of these 4
variables were performed within the linear regression models estimating mean 12-week
MENQOL as a function of treatment arm, the covariate of interest and the interaction
between treatment assignment and covariate; models were adjusted for clinical center,
concurrent intervention assignment, and baseline outcome value. Nominal p-values were
calculated for the 8 potential interactions examined. Thus, less than one p-value would be
expected to be statistically significant at the 0.05 level by chance alone.
Reported p-values are based on the Wald statistic, with 2-sided p-value ≤0.05 considered
statistically significant. Analyses were conducted using SAS Version 9.2 (SAS Institute,
Cary, NC).
RESULTS
Sample sizes by intervention assignments, available MENQOL data for analyses, and study
completion are shown in Figure 1. Overall, 78% met the yoga adherence threshold, 83% met
the threshold for adherence to exercise;22-24 82% of women randomized to omega-3, and
79% of women randomized to placebo took at least 80% of dispensed pills.25
There were no significant differences between the randomized treatment groups in baseline
characteristics (Table 1) with the exception of age (exercise group older than usual activity);
and ethnicity (omega-3 group more likely to be white than placebo).
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Additional factors that might affect menopause-related QOL were compared at baseline
(Table 2). There were no differences between groups with the exception that women
randomized to exercise had a higher mean PEG score than women in the usual activity
group, and that women randomized to omega-3s had a lower mean FSFI score, than women
in the placebo group. Overall, 35% percent had mild/moderate depressive symptoms, 27%
had mild/moderate anxiety, and 40% had poor sleep quality. Mean hot flash interference
score was 32.4 (HFRDIS range 0-100). Stress levels were relatively low with an overall
mean PSS score of 13.8 (SD 7.0), similar to the standard norm of 13.7 (SD 6.6).37 Mean
PEG score was low at 1.1 (SD 1.8). Sexual function was relatively poor with a mean FSFI of
18.4 (SD 10.5).
Mean total MENQOL score was 3.8 (range 1-8) at baseline, with no between-group
differences at baseline. The yoga intervention resulted in significantly greater improvement
in MENQOL scores at 12-weeks as compared to the usual activity group in adjusted linear
regression models (p=0.02), but there were no group differences between exercise and usual
activity or omega-3 and placebo (Table 3). The mean difference in change from baseline to
12-weeks in total MENQOL score for the yoga intervention, as compared to usual activity,
was -0.3 (95% confidence interval (CI) -0.6, 0.0). Statistically significant differences in
MENQOL domain scores favoring the yoga intervention were observed for the Vasomotor
(-0.3; 95% CI -0.8, 0.2; p=0.02) and Sexual domains (-0.5; 95% CI -1.0, 0.0; p=0.03). For
exercise and omega-3, evaluation of the four MENQOL domains showed only a statistically
significant treatment group difference favoring the exercise group for the Physical domain
(-0.2; 95% CI -0.5, 0.0; p=0.02), and no domain scores varied between the omega-3 and
placebo groups.
There was no significant difference between yoga and usual activity when sexual function
was evaluated by the validated and more detailed FSFI (p=0.58) (Table 4). HFRDIS scores
declined (i.e. improved) in the yoga group relative to usual activity by 12 weeks (group
difference -3.4; 95% CI -9.0, 2.3; p=0.03), but changes in stress and pain did not differ
between the yoga and usual activity groups. Hot flash interference, stress, pain and sexual
function showed no improvement with exercise or omega-3 interventions over usual care or
placebo, respectively.
COMMENT
Little evidenced-based information is available for women with menopausal symptoms
considering behavioral changes to improve quality of life. We found that, relative to usual
activity, a 12-week program of yoga slightly improved menopause-related QOL and reduced
the extent to which hot flashes interfered with a woman’s daily function among women with
VMS, but that exercise and omega-3 supplements had no effect on these measures. Among
the individual MENQOL domains, we found slight benefit for VMS and sexual function
domains (but not for the physical and psychosocial domains) from the yoga intervention and
benefit for only the physical domain for the exercise intervention.
All of the significant menopause-related QOL differences and the difference observed in the
hot flash daily interference measure with the yoga intervention were small, and therefore
clinical relevance of our findings may be modest at best. For example, mean total MENQOL
score at baseline was 3.8 (range 1-8) with a mean diminution of 0.9 in the yoga intervention
and a decrease of 0.6 in the usual activity group at 12-weeks. Significant MENQOL domain-
specific differences observed (VMS, physical, sexual) were of similarly small magnitudes
and were not supported by other individual validated measures of factors potentially related
to QOL: pain (PEG), sexual function (FSFI), and VMS daily diaries.22 While similar
questionnaires may purport to measure the same outcomes, differences in the way they are
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delivered (e.g. diary vs. global scale) may lead women to respond differently (counts vs.
global impression). Aside from these differences, the statistically significant differences
found could be due to chance alone.
Few studies have evaluated menopause-related QOL in menopausal women practicing yoga.
Most were conducted in special populations – women with insomnia,11 breast cancer,12 and
those specifically taking aromatase inhibitors.38 All found benefit, but studies were limited
by an extremely high withdrawal rate (23% overall, 63% yoga group),11 and wait-list12 or
no controls;38 results should be interpreted with caution. A 3-arm trial (n=162) found a
“positive affect” on QOL in both walking and yoga intervention groups compared to wait-
list controls.39 We previously reported that among healthy women, 12 weeks of yoga class
plus home practice did not improve VMS frequency or bother compared with usual activity,
but yoga was associated with minor improvements in sleep quality, insomnia symptoms, and
depressive symptoms.22 In the analyses reported here, we found modest diminished hot flash
interference with daily activities, comparing yoga to usual activity, findings consistent with
two smaller studies that lacked control groups.7,9 The inclusion of control groups in our
study with opportunity for expectation of benefit (all women received a pill - placebo or
omega 3 fatty acid tablets) is critical for interpreting these mixed findings.
Consistent with other studies on exercise in midlife, we found that the exercise intervention
improved the MENQOL physical function domain as compared with usual activity, but
exercise was not associated with improvement in overall menopause-related QOL.40,41 Two
studies reporting on health-related QOL among postmenopausal women found benefit with
increased physical activity, but specifics as to whether women were experiencing significant
VMS, as in our study population, were lacking in one,13 and the other evaluated breast
cancer survivors with a home-based exercise program.42 In addition, both studies used a
different QOL measure that is not specific to menopause-related symptoms. Consistent with
the lack of menopause-related QOL benefit from exercise, we did not observe improvement
in hot flash interference, stress, pain or sexual function.
In our study, omega-3 supplements were not associated with improvements in menopausal
QOL, hot flash interference, stress, pain or sexual function.
The rationale for evaluating whether yoga and or exercise improves QOL is based on the
hypothesis that sympathetic nervous system (SNS) and parasympathetic nervous (PNS)
system imbalances occur at midlife. Behavioral interventions impact both SNS and PNS
function and stress reactivity, supporting the hypothesis that yoga and/or exercise might shift
the balance toward sympathetic dominance and improve perceived QOL. Yoga or exercise
could also decrease autonomic arousal through changes in circulating neurotransmitters and
hormone concentrations,43 leading to improved perceived QOL. In addition, improved QOL
with exercise is hypothesized to occur through increasing circulation of beta endorphins, or
potentially as a relief or distraction from worries or stress.44,45 Analyses of physiologic
measures of the SNS and PNS balance (heart rate variability and salivary cortisol) among
our participants are ongoing to guide biologic interpretation of our findings.
Limitations of our study deserve mention. Although women were recruited from
community-based samples, participants were primarily sedentary, had at least two hot
flashes/day and were compensated for their participation. Generalizability to other
populations must be thoughtfully considered. The impact of reimbursement is uncertain.
Women who self-selected, and paid for, similar classes in the community might be more
(due to their financial investment) or less (due to lack of reimbursement) motivated to
adhere to the program. They may have been a select group motivated to seek treatment and
had treatment expectations. Mean sum baseline MENQOL scores for all groups were 3.8
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(yoga, exercise and usual activity), comparable to another MsFLASH study evaluating an
SSRI vs placebo (3.7-3.9) 46, but lower than a study evaluating hormonal therapies
(4.4-4.5) 47. The 12-week treatment interval was brief, but most likely sufficient for
determining long-term non-hormonal treatment efficacy.42 We examined multiple potential
moderating factors of treatment response, but other factors likely exist. We cannot rule out
the possibility that other more intensive yoga or exercise regimens or a different omega-3
formulation might have a more salutary effect on menopause-related QOL. This study
analyzed multiple outcomes, thus significant findings may be due to chance.
Study strengths are that the interventions were designed specifically for midlife women,
both peri- and postmenopausal women, the omega-3 formulation had excellent quality
control data, the sample size was large, with a low dropout rate, and participants were
adherent to therapy. All participants took either omega-3 or placebo capsules, thus providing
the expectancy of benefit in all women. Validated measures for VMS, sleep, stress, pain,
sexual function, and mood assisted in the interpretation of MENQOL findings. The majority
of VMS intervention trials have not evaluated treatment effects on menopause-related QOL.
For those that have, the available QOL measures are numerous and of variable quality.48
Our rationale for using the MENQOL for the sFLASH trials is based on the breadth of its
domains, salutary psychometric properties, brevity and sensitivity to change over time.
All women become menopausal and many seek medical advice on ways to improve quality
of life; little evidence-based information exists. Future studies are needed to better
understand the physiologic basis for and maximization of benefit from behavioral therapies
for menopausal symptoms. Providers may advise women that yoga slightly improves
menopause quality of life; exercise and omega-3 supplements do not.
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Figure 1. Participant recruitment
* Some women had more than one reason for exclusion
1
 Participants were randomized to yoga, exercise, and usual activity in a 3: 3:4 ratio
MENQOL Total Data by MS FLASH Treatment Assignment at baseline and Week 121
1Week 12 totals include only those participants who also have data at baseline
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